Allergic rhinitis
Conditions
Interventions
Treatment group A:SCIT and vitamin D3 in short-term
Treatment group B:SCIT and vitamin D3 in long-term
Treatment group C:SCIT
Sponsors
the Third Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
5 Years to 18 Years
Inclusion criteria
Inclusion criteria: (1) 5 years old =0.35 kU/L) caused by house dust mite (HDM); (4) Receiving standard anti-allergy medication for at least 1 year before enrollment; (5) Serum 25 (OH) D in normal levels .
Exclusion criteria
Exclusion criteria: (1) Subjects and/or parents/legal guardians have a low degree of expected compliance with the trial procedures or are unable to understand the instructions/trial documents; (2) Randomized treatment has been carried out before this trial; (3) A clear history of serious adverse reactions or anaphylactic shock has occurred in the past use of AIT; (4) Received dust mite-specific immunotherapy in the past 5 years; (5) Current or prior treatment with biologics (6) Patients with severe or uncontrolled asthma (FEV1<70% predicted) and the presence of irreversible airflow obstruction; (7) Patients using ß receptor blockers or angiotensin-converting enzyme (ACE) inhibitors; (8) Patients with severe autoimmune diseases, including immunodeficiency diseases and autoimmune diseases such as AIDS and inflammatory bowel disease, as well as patients with active infection, diabetes, gastric ulcer, etc.; (9) Patients with severe psychological disorders or patients who are not at risk of receiving treatment; Severe cardiovascular disease; Malignancy; (10) Patients supplemented with vitamin D.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analog Scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Medical Score; | — |
Countries
China
Contacts
Public ContactZhang Pingping
the Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed